AMBRI Ltd.; weitere ziemlich unentdeckte NanoPerle
13.02.04 14:13
#201
taisir
wow, was sehe ich hier
hat sich doch gut erholt, anscheint ist das interesse an der Akttie hier in D auch wieder da., und der Skandal mit dem Illegalem Handel ist auch abgeflacht, den der Kurs wir in AUS gemacht.
die ask blöcke scheinen jetzt verteilt zu sein und ich denke nicht dass es weiter runtergeht. so sehe ich das
die ask blöcke scheinen jetzt verteilt zu sein und ich denke nicht dass es weiter runtergeht. so sehe ich das
13.02.04 14:15
#202
taisir
meiko, wenn die empfehlung
kommt dann sind wir schon wieder über 30!
die Empfehlung zu Obducat kamm bei 40 cent, so weit ich weiss.
weiss das jemand genau, wann die empfehlung vom Auktionär zu OBDC kam? will mal paralelleen ziehen für mich
die Empfehlung zu Obducat kamm bei 40 cent, so weit ich weiss.
weiss das jemand genau, wann die empfehlung vom Auktionär zu OBDC kam? will mal paralelleen ziehen für mich
13.02.04 14:19
#203
Meiko
Ich denke die geht auf keinen Fall unter 0,22!
Vermute dass wir nach der Konsolidierung und der Empfehlung im Aktionär nächste Woche die 0,30 hinter uns lassen.
13.02.04 14:31
#206
taisir
da war das beste ;)
sollen die weiter pennen, wenn wir weg rennen mit dem cash , hehe
hast du PRVH verkauft?!?
hast du PRVH verkauft?!?
13.02.04 15:59
#207
taisir
na bitte 0,25 EUR in berlin
15:39:00 0,246 2 800 Berlin-Bremen
15:26:00 0,246 8 000 Berlin-Bremen
15:25:00 0,246 20 000 Berlin-Bremen
14:40:00 0,244 10 000 Berlin-Bremen
14:39:00 0,244 26 000 Berlin-Bremen
14:34:00 0,244 20 000 Berlin-Bremen
14:33:00 0,244 15 000 Berlin-Bremen
14:31:00 0,242 10 000 Berlin-Bremen
14:24:00 0,246 20 000 Berlin-Bremen
14:18:00 0,246 20 000 Berlin-Bremen
14:09:00 0,245 4 000 Berlin-Bremen
14:00:00 0,247 20 000 Berlin-Bremen
13:59:00 0,247 35 000 Berlin-Bremen
15:26:00 0,246 8 000 Berlin-Bremen
15:25:00 0,246 20 000 Berlin-Bremen
14:40:00 0,244 10 000 Berlin-Bremen
14:39:00 0,244 26 000 Berlin-Bremen
14:34:00 0,244 20 000 Berlin-Bremen
14:33:00 0,244 15 000 Berlin-Bremen
14:31:00 0,242 10 000 Berlin-Bremen
14:24:00 0,246 20 000 Berlin-Bremen
14:18:00 0,246 20 000 Berlin-Bremen
14:09:00 0,245 4 000 Berlin-Bremen
14:00:00 0,247 20 000 Berlin-Bremen
13:59:00 0,247 35 000 Berlin-Bremen
13.02.04 16:07
#209
Meiko
Das Orderbuch sieht wieder sehr gut aus,
Bid hat endlich mal Übergewicht, es scheint sich ein nächstes Obducat anzubahnen, aber warten wir erst mal ab, was die Aussis machen bevor wir hier zu grosse Töne spucken.
13.02.04 20:59
#210
taisir
so, SK bei 0,25!! jetzt müssen nur die Ausis
mispielen, dann wirds hier auch laufen, und zwar gewaltig. wir habe heute gesehen, dass ein grosse interesse an der AKtie besteht, bei 2,2 mio Umsatz!
also, alle augen auf Sonntag Nacht
also, alle augen auf Sonntag Nacht
14.02.04 09:03
#211
P340
Ambri Handel untersagt, Aktien eingezogen ?!
Hab' mich von Taisir und Meiko verleiten lassen, doch noch Ambri zu kaufen und nun das:
Ambri Handel untersagt, Aktien eingezogen ?!
So könnte die Überschrift lauten, wenn man die Seiten bei Ambri richtig interpretiert.
Hat jemand von der Berliner Börse nähere Informationen ?
Ist das überhaupt legal Aktien ohne Zustimmung der Firma an beliebigen Börsenplätzen anzubieten ? Oder mach' ich mir da umsonst Sorgen ?
Danke für Infos.
P340
Ambri Handel untersagt, Aktien eingezogen ?!
So könnte die Überschrift lauten, wenn man die Seiten bei Ambri richtig interpretiert.
Hat jemand von der Berliner Börse nähere Informationen ?
Ist das überhaupt legal Aktien ohne Zustimmung der Firma an beliebigen Börsenplätzen anzubieten ? Oder mach' ich mir da umsonst Sorgen ?
Danke für Infos.
P340
14.02.04 12:45
#212
P340
Ambri Hab mich mal auf die Suche gemacht ....
Wodurch erklärt sich denn nun eigentlich der Kursanstieg ?
Folgende Altlasten habe ich gefunden :
Ambri falls after chief quits
March 28 2003
By Ian Porter
Diagnostic equipment developer Ambri has been dealt another heavy blow with news that its chief executive has resigned, only weeks after auditors questioned the company's status as a going concern.
Ambri shares slumped 3.5¢ to a record low of 38.5¢ on Tuesday after news that Joe Shaw had quit. Yesterday the shares recovered slightly to 39¢.
Dr Shaw had been chief executive for four years. His departure comes as the company struggles to find more cash to enable it to bring its equipment to market.
Ambri had just $13 million in the bank at December 31. It spent $11.6 million in the December half as it prepared to start production of its diagnostic system for use in hospital emergency departments.
Former parent company Ansell still holds a 17.2 per cent stake in Ambri.
In a note to the audit review of the interim results, auditors KPMG said there was "significant uncertainty" about whether Ambri would continue as a going concern.
At the time, directors said it was appropriate to prepare the report on a going concern basis "considering the company's record of raising funds based on the (company's) business plan and its unique technology".
Chairman John Eady said yesterday Dr Shaw had resigned to return to the US.
He said the board had appointed David Cornelius as acting chief executive and managing director "pending the appointment of a new, permanent CEO".
Mr Cornelius was a non-executive director of Ambri. He was elected to the board as the nominee of two US companies, Dow Corning and Genencor. Ambri has licensed the two to use its technology in certain applications.
The launch of Ambri's products was scheduled for last year but the company ran into difficulties preparing for mass production.
The diagnostic system comprises a reader unit and disposable cartridges that detect a range of chemicals and markers in blood samples. Production of the cartridges was more complex that expected, shareholders were told at the annual meeting.
Dr Shaw took responsibility and apologised for the delay.
Folgende Altlasten habe ich gefunden :
Ambri falls after chief quits
March 28 2003
By Ian Porter
Diagnostic equipment developer Ambri has been dealt another heavy blow with news that its chief executive has resigned, only weeks after auditors questioned the company's status as a going concern.
Ambri shares slumped 3.5¢ to a record low of 38.5¢ on Tuesday after news that Joe Shaw had quit. Yesterday the shares recovered slightly to 39¢.
Dr Shaw had been chief executive for four years. His departure comes as the company struggles to find more cash to enable it to bring its equipment to market.
Ambri had just $13 million in the bank at December 31. It spent $11.6 million in the December half as it prepared to start production of its diagnostic system for use in hospital emergency departments.
Former parent company Ansell still holds a 17.2 per cent stake in Ambri.
In a note to the audit review of the interim results, auditors KPMG said there was "significant uncertainty" about whether Ambri would continue as a going concern.
At the time, directors said it was appropriate to prepare the report on a going concern basis "considering the company's record of raising funds based on the (company's) business plan and its unique technology".
Chairman John Eady said yesterday Dr Shaw had resigned to return to the US.
He said the board had appointed David Cornelius as acting chief executive and managing director "pending the appointment of a new, permanent CEO".
Mr Cornelius was a non-executive director of Ambri. He was elected to the board as the nominee of two US companies, Dow Corning and Genencor. Ambri has licensed the two to use its technology in certain applications.
The launch of Ambri's products was scheduled for last year but the company ran into difficulties preparing for mass production.
The diagnostic system comprises a reader unit and disposable cartridges that detect a range of chemicals and markers in blood samples. Production of the cartridges was more complex that expected, shareholders were told at the annual meeting.
Dr Shaw took responsibility and apologised for the delay.
14.02.04 15:57
#214
P340
@Meiko , @taisir Ambri NanoChronologie
Chronologie
August 2001 Ansell verkauft Anteile an Ambri an Optecom
August 2001 Optecom benennt sich in Ambri Ltd. um
Dez. 2002 Dr John Eady Ambri's non-executive director geht zur Konkurrenz
Gradipore.com wo er allerdings auch nicht lange bleibt aufgrund des
katstrophalen Zustandes des Aktienkurses
März 2003 Joe Shaw President und CEO von Ambri geht nach Amerika zu AAGI
(http://www.ausamericangroup.com/aboutus.php) und trifft
dort Andrew Mc. Crea wieder, ex. Director Corporate Strategy und Börsenprofi
Dez. 2003 Ambri von Ansell-Mutter bereits fast abgeschrieben
Wo kommen denn die 20 Mio. bei Ambri her ? (20 Mio. bank bill = Wechsel?)
Im Detail :
2001 Ansell verkauft Anteil an Ambri an Optecom
Most of the major problems which have dragged the Company down in recent year are now either behind it, or close to resolution. Ambri's biosensor technology business was sold to Optecom Limited to reduce cash commitments going forward.
We believe that the prospects of successful commercialsisation of the technology are very good, but continuing to bear the full risks of the ongoing R&D was not appropriate for the company.
Dezember 2002
Gradipore strengthens board
Australia's Gradipore Ltd has appointed Dr John Eady as non-executive director.
Dr Eady is currently chairman of Ambri Ltd, a newly-listed biotechnology company which, as with Gradipore, is in the process of commercializing its intellectual property.
Recently, he has also advised a US-based company on revitalising its management and to achieve best practice.
During his career, Dr Eady spent more than 26 years with CRA and its subsidiaries. He is an experienced director, having held directorships with the Australia Industry Research and Development Board, Comalco Aluminium, Comalco Bell Bay Pty Ltd, Southern Aluminium Ltd, the AIDC, and Comalco and Rio Tinto, Japan.
Gradipore is a biotechnology company that researches, develops, manufactures and markets haematological and separation technologies principally to provide increased efficiency for research and development for the life science market throughout the world.
Intention to convene a General Meeting of Shareholders
30 May 2003
Gradipore Limited has received a letter from Mr John Manusu, a director of the company, advising that it is his intention to convene a general meeting of the company on 30 June 2003. A draft Notice of General Meeting, which accompanied the letter, includes resolutions to appoint 2 new directors and remove 4 current serving directors.
The letter and Notice advise that the following are to be proposed for election as directors:
· Mr John Fernandez
· Mr Gregory Desmond Fagan
and the following to be removed:
· Mr Jeremy Davis
· Dr John Eady
· Mr Robert Lieb
· Mr Leslie Webb
März 2003 Joe Shaw geht nach Amerika zu AAG http://www.ausamericangroup.com
und trifft dort Andrew Mc. Crea wieder !
Auszug aus Mc.Creas Lebenslauf :
Currently, a principal of Aus-American Group Inc, an international consulting firm. Previously, Mr McCrea was Director Corporate Strategy, Ambri Limited a biotechnology company listed on the Australian Stock Exchange. From 1998-2001, Mr McCrea was CEO of Qpax Inc. in New York, NY a software technology firm until it was acquired by Worldspan Inc. Previously, from 1993-98, Mr McCrea was founder and CEO of Permanent Capital Sdn Bhd – an investment banking group in Kuala Lumpur, Malaysia. Previously, Mr McCrea was a Senior Consultant for Fairgill Investments Pty Ltd – an investment company of members of the Fairfax family in Sydney, Australia. Previous to that, Mr McCrea worked on Wall Street for a division of Citicorp NA investment bank (Citibank) as a Vice President – International division.
Auszug aus Shaws Lebenslauf
From April 1987 Dr. Shaw was Vice President and Head of diagnostics of Quadra Logic Technologies, Inc., a company listed on NASDAQ and the Toronto Stock Exchange. Subsequently Dr. Shaw founded Quantech Ltd. a medical diagnostics biosensor company originally taken public in Italy and subsequently on NASDAQ where it trades today. In July 1999 Dr Shaw was appointed President & CEO of Ambri Limited. He has broad international experience in biotechnology and has extensive experience in Canada, Australia, Italy and the United States as a senior executive in medical corporations
Ende 2003
aus Ansell Finanzreports :
Non Recurring Items
1. A non-cash write-down of US$5.3 million for equipment from the now closed Massillon manufacturing facility. A provision had been formally approved by the Board as part of the 2001 restructure, but not made pending evaluation of alternative uses for this surgical glove manufacturing equipment. However, following successful conversion of examination glove production lines in Colombo, and further additions currently planned, it is now clear that this equipment will not be required.
-5-
2. A further decline in the share price of Ambri Ltd. from A37.5¢ to the market value at 31 December, 2003 of A25¢ a share, resulted in an US$0.7 M non-cash mark down of Ansell’s investment. The book value of this investment now stands at US$1.5 M.
3. There was a US$5.5 million cash gain from a refund of Australian Sales Tax related to a discontinued business.
In addition to the activities of our business units mentioned below,
we continued to make good progress in reducing the cost of operating
our corporate offices, almost halving the cost from the previous year
on a comparable basis.
The total Company result was achieved after a $6.1 million (US$3.6 million)
non-cash write-down to market value at 30 June 2003 of our residual
non-core investment in Ambri Limited.
We have worked hard to develop a new culture that is more entrepreneurial,
analytical and results driven, and we are continuing to concentrate on
improving our existing operating efficiencies and accelerating restructuring
programs in each of the regions – the Americas, Europe and Asia Pacific –
in which we operate.
Ansell’s non-core investment in Ambri Limited, which
resulted from the sale by Ansell in August 2001 of its
former wholly-owned subsidiary, Ambri Pty Limited,
has been written down from the original float price
of $1.11 per share to the 30 June 2003 market price
of $0.375. A non-cash write-off of $6.1 million
(US$3.6 million) in FY2003 reduced the book value
of Ansell’s investment in Ambri Limited to $3.1 million
(US$2.1 million).
August 2001 Ansell verkauft Anteile an Ambri an Optecom
August 2001 Optecom benennt sich in Ambri Ltd. um
Dez. 2002 Dr John Eady Ambri's non-executive director geht zur Konkurrenz
Gradipore.com wo er allerdings auch nicht lange bleibt aufgrund des
katstrophalen Zustandes des Aktienkurses
März 2003 Joe Shaw President und CEO von Ambri geht nach Amerika zu AAGI
(http://www.ausamericangroup.com/aboutus.php) und trifft
dort Andrew Mc. Crea wieder, ex. Director Corporate Strategy und Börsenprofi
Dez. 2003 Ambri von Ansell-Mutter bereits fast abgeschrieben
Wo kommen denn die 20 Mio. bei Ambri her ? (20 Mio. bank bill = Wechsel?)
Im Detail :
2001 Ansell verkauft Anteil an Ambri an Optecom
Most of the major problems which have dragged the Company down in recent year are now either behind it, or close to resolution. Ambri's biosensor technology business was sold to Optecom Limited to reduce cash commitments going forward.
We believe that the prospects of successful commercialsisation of the technology are very good, but continuing to bear the full risks of the ongoing R&D was not appropriate for the company.
Dezember 2002
Gradipore strengthens board
Australia's Gradipore Ltd has appointed Dr John Eady as non-executive director.
Dr Eady is currently chairman of Ambri Ltd, a newly-listed biotechnology company which, as with Gradipore, is in the process of commercializing its intellectual property.
Recently, he has also advised a US-based company on revitalising its management and to achieve best practice.
During his career, Dr Eady spent more than 26 years with CRA and its subsidiaries. He is an experienced director, having held directorships with the Australia Industry Research and Development Board, Comalco Aluminium, Comalco Bell Bay Pty Ltd, Southern Aluminium Ltd, the AIDC, and Comalco and Rio Tinto, Japan.
Gradipore is a biotechnology company that researches, develops, manufactures and markets haematological and separation technologies principally to provide increased efficiency for research and development for the life science market throughout the world.
Intention to convene a General Meeting of Shareholders
30 May 2003
Gradipore Limited has received a letter from Mr John Manusu, a director of the company, advising that it is his intention to convene a general meeting of the company on 30 June 2003. A draft Notice of General Meeting, which accompanied the letter, includes resolutions to appoint 2 new directors and remove 4 current serving directors.
The letter and Notice advise that the following are to be proposed for election as directors:
· Mr John Fernandez
· Mr Gregory Desmond Fagan
and the following to be removed:
· Mr Jeremy Davis
· Dr John Eady
· Mr Robert Lieb
· Mr Leslie Webb
März 2003 Joe Shaw geht nach Amerika zu AAG http://www.ausamericangroup.com
und trifft dort Andrew Mc. Crea wieder !
Auszug aus Mc.Creas Lebenslauf :
Currently, a principal of Aus-American Group Inc, an international consulting firm. Previously, Mr McCrea was Director Corporate Strategy, Ambri Limited a biotechnology company listed on the Australian Stock Exchange. From 1998-2001, Mr McCrea was CEO of Qpax Inc. in New York, NY a software technology firm until it was acquired by Worldspan Inc. Previously, from 1993-98, Mr McCrea was founder and CEO of Permanent Capital Sdn Bhd – an investment banking group in Kuala Lumpur, Malaysia. Previously, Mr McCrea was a Senior Consultant for Fairgill Investments Pty Ltd – an investment company of members of the Fairfax family in Sydney, Australia. Previous to that, Mr McCrea worked on Wall Street for a division of Citicorp NA investment bank (Citibank) as a Vice President – International division.
Auszug aus Shaws Lebenslauf
From April 1987 Dr. Shaw was Vice President and Head of diagnostics of Quadra Logic Technologies, Inc., a company listed on NASDAQ and the Toronto Stock Exchange. Subsequently Dr. Shaw founded Quantech Ltd. a medical diagnostics biosensor company originally taken public in Italy and subsequently on NASDAQ where it trades today. In July 1999 Dr Shaw was appointed President & CEO of Ambri Limited. He has broad international experience in biotechnology and has extensive experience in Canada, Australia, Italy and the United States as a senior executive in medical corporations
Ende 2003
aus Ansell Finanzreports :
Non Recurring Items
1. A non-cash write-down of US$5.3 million for equipment from the now closed Massillon manufacturing facility. A provision had been formally approved by the Board as part of the 2001 restructure, but not made pending evaluation of alternative uses for this surgical glove manufacturing equipment. However, following successful conversion of examination glove production lines in Colombo, and further additions currently planned, it is now clear that this equipment will not be required.
-5-
2. A further decline in the share price of Ambri Ltd. from A37.5¢ to the market value at 31 December, 2003 of A25¢ a share, resulted in an US$0.7 M non-cash mark down of Ansell’s investment. The book value of this investment now stands at US$1.5 M.
3. There was a US$5.5 million cash gain from a refund of Australian Sales Tax related to a discontinued business.
In addition to the activities of our business units mentioned below,
we continued to make good progress in reducing the cost of operating
our corporate offices, almost halving the cost from the previous year
on a comparable basis.
The total Company result was achieved after a $6.1 million (US$3.6 million)
non-cash write-down to market value at 30 June 2003 of our residual
non-core investment in Ambri Limited.
We have worked hard to develop a new culture that is more entrepreneurial,
analytical and results driven, and we are continuing to concentrate on
improving our existing operating efficiencies and accelerating restructuring
programs in each of the regions – the Americas, Europe and Asia Pacific –
in which we operate.
Ansell’s non-core investment in Ambri Limited, which
resulted from the sale by Ansell in August 2001 of its
former wholly-owned subsidiary, Ambri Pty Limited,
has been written down from the original float price
of $1.11 per share to the 30 June 2003 market price
of $0.375. A non-cash write-off of $6.1 million
(US$3.6 million) in FY2003 reduced the book value
of Ansell’s investment in Ambri Limited to $3.1 million
(US$2.1 million).
16.02.04 09:03
#215
taisir
moin gemeinde
halben cent haben die ausis verloren, also schluss bei 0,375.
d.h. es war eigentlich kein grosser verkaufsdruck in AUS da - kann man positiv sehen. Oder es ist kein Interese an der Aktie mehr vorhanden, das volumen hat zurückgesetz. hmm...
bin gespannt was die TAge noch passiert, ich werde noch auf jedenfall halten.
Ich schätze dass wir um 24-25 cents herumpendeln werden oder es könnte leicht ins plus gehen, bestenfalls.
d.h. es war eigentlich kein grosser verkaufsdruck in AUS da - kann man positiv sehen. Oder es ist kein Interese an der Aktie mehr vorhanden, das volumen hat zurückgesetz. hmm...
bin gespannt was die TAge noch passiert, ich werde noch auf jedenfall halten.
Ich schätze dass wir um 24-25 cents herumpendeln werden oder es könnte leicht ins plus gehen, bestenfalls.
16.02.04 09:20
#216
P340
moin @taisir
Hast Du meine recherchen gelesen ?
Weiß Du wo die 20 Mio. herkommen ?
Danke für Info.
P340
Weiß Du wo die 20 Mio. herkommen ?
Danke für Info.
P340
16.02.04 09:50
#217
taisir
also 0,26 ist gut, +4%
hier die letzten Trades, man achte auf den ertsen Trade in BB!!
09:22:00 0,25 30 000 Stuttgart
09:21:00 0,26 60 000 Berlin-Bremen
09:20:00 0,25 2 500 Stuttgart
09:16:00 0,25 42 000 Stuttgart
09:11:00 0,26 4 000 München
09:06:00 0,26 30 500 Berlin-Bremen
09:05:00 0,26 36 500 München
09:02:00 0,25 20 000 Stuttgart
09:00:00 0,25 18 800 Stuttgart
09:00:00 0,26 293 420 Berlin-Bremen - ca.77000€!
09:22:00 0,25 30 000 Stuttgart
09:21:00 0,26 60 000 Berlin-Bremen
09:20:00 0,25 2 500 Stuttgart
09:16:00 0,25 42 000 Stuttgart
09:11:00 0,26 4 000 München
09:06:00 0,26 30 500 Berlin-Bremen
09:05:00 0,26 36 500 München
09:02:00 0,25 20 000 Stuttgart
09:00:00 0,25 18 800 Stuttgart
09:00:00 0,26 293 420 Berlin-Bremen - ca.77000€!
16.02.04 09:53
#218
taisir
p340
weisst du es selber net oder weisst du es doch?
muss nochmal genau durchlesen was du da gefunden hast, sieht so aus als ob du aus verschiedenen Interviews zusammengestellt hast..
muss nochmal genau durchlesen was du da gefunden hast, sieht so aus als ob du aus verschiedenen Interviews zusammengestellt hast..
16.02.04 12:45
#219
azel
kann mihr einer..
die marktkapetalisierung und den umsatz des unternehmens sagen wkn 938156 trotz austra. läuft das papier echt gut.die müßen nachziehen morgen!danke im vorraus!
16.02.04 16:09
#220
taisir
noch ein brocken
all frick/förtsch :-) 15:23:00 0,26 201 003 Berlin-Bremen
gut, preiset bald ambri an, aber erst bei 40 cent!
@azel -
mk - 44mio; mit 167 mio shares, bei 0,265$
besitzten ca 80 Patente und 55 Nebenpatente
sehe den Stabilen Kurs in D als äusserst positiv!!! Jetzt müssen wirklich nur die Ausis ins Plus drehen! Datapharm erholt sich auch grade :)
taisir
gut, preiset bald ambri an, aber erst bei 40 cent!
@azel -
mk - 44mio; mit 167 mio shares, bei 0,265$
besitzten ca 80 Patente und 55 Nebenpatente
sehe den Stabilen Kurs in D als äusserst positiv!!! Jetzt müssen wirklich nur die Ausis ins Plus drehen! Datapharm erholt sich auch grade :)
taisir
16.02.04 17:23
#221
azel
@taisir
danke!verdiennen die eigentlich schon was?oder schreiben die noch rote zahlen?hört sich sehr gut an mit der MK.da sind kurzfritig bestimmt 100% drin!MFG AZEL
16.02.04 21:07
#222
Pauli
bin heute einestiegen
zu 0,26 - hätte ich abends natürlich günstiger haben können, aber...
Bin durch den Aktionär aufmerksam geworden und habe Gott sei Dank etwas gewartet. Heute schien mir dann ein günstiger Zeitpunkt zu sein, nachdem sich der Kurs beruhigt hatte. Habe mit Interesse die Infos hier und anderswo gelesen. Bin sehr gespannt, ob das nun was wird...
Bin durch den Aktionär aufmerksam geworden und habe Gott sei Dank etwas gewartet. Heute schien mir dann ein günstiger Zeitpunkt zu sein, nachdem sich der Kurs beruhigt hatte. Habe mit Interesse die Infos hier und anderswo gelesen. Bin sehr gespannt, ob das nun was wird...
16.02.04 21:14
#223
azel
@pauli
in welcher ausgabe sind die den empfohlen worden?habe ich nicht gelessen!MFG AZEL